Date | Name | Title | Filing | Type | Shares Traded | Price Range | Total Held |
---|---|---|---|---|---|---|---|
Jul 25, 2017 | Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 14,000 | -- | -- | |
Jul 25, 2017 | Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 14,000 | $15.75 | 60,974 | |
Jul 25, 2017 | Director | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 12,879 | $17.12 | 48,095 | |
Jul 25, 2017 | Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 14,000 | -- | -- | |
Jul 25, 2017 | Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 14,000 | $15.75 | 83,127 | |
Jul 25, 2017 | Director | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 12,879 | $17.12 | 70,248 | |
Jul 25, 2017 | Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 14,000 | -- | -- | |
Jul 25, 2017 | SVP, GM - Oncology | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 432 | $17.12 | 17,608 | |
Jul 25, 2017 | SVP and General Counsel | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 437 | $17.12 | 31,242 | |
Jul 24, 2017 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 316 | $16.00 | 316 |
For recent transactions, including derivative transactions, see our Section 16 SEC filings page.